BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 7852952)

  • 1. Homologous and heterologous neutralization antibody responses after immunization with Japanese encephalitis vaccine among Taiwan children.
    Ku CC; King CC; Lin CY; Hsu HC; Chen LY; Yueh YY; Chang GJ
    J Med Virol; 1994 Oct; 44(2):122-31. PubMed ID: 7852952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Seroepidemiology of Japanese encephalitis viral infection among 3-6 years old children from mountainous and plains townships located in the northern, central, southern and eastern Taiwan].
    Hsu LC; Wu YC; Lin SR; King CC; Ho MS; Lu CF; Hsu HM; Chen KT; Horng CB
    Zhonghua Min Guo Wei Sheng Wu Ji Mian Yi Xue Za Zhi; 1997 Aug; 30(3):194-206. PubMed ID: 10592824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partially neutralizing potency against emerging genotype I virus among children received formalin-inactivated Japanese encephalitis virus vaccine.
    Fan YC; Chen JM; Chiu HC; Chen YY; Lin JW; Shih CC; Chen CM; Chang CC; Chang GJ; Chiou SS
    PLoS Negl Trop Dis; 2012; 6(9):e1834. PubMed ID: 23029592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of cross-protection against two wild-type Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine.
    Wu CJ; Huang HW; Tao MH
    Vaccine; 2003 Sep; 21(25-26):3938-45. PubMed ID: 12922129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-protection elicited by primary and booster vaccinations against Japanese encephalitis: a two-year follow-up study.
    Erra EO; Askling HH; Yoksan S; Rombo L; Riutta J; Vene S; Lindquist L; Vapalahti O; Kantele A
    Vaccine; 2013 Dec; 32(1):119-23. PubMed ID: 24176496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sero-Molecular Epidemiology of Japanese Encephalitis in Zhejiang, an Eastern Province of China.
    Pan JR; Yan JY; Zhou JY; Tang XW; He HQ; Xie RH; Mao HY; Zhang YJ; Xie SY
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004936. PubMed ID: 27560360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of a Japanese encephalitis chimeric virus vaccine as a booster dose after primary vaccination with SA14-14-2 vaccine in Thai children.
    Janewongwirot P; Puthanakit T; Anugulruengkitt S; Jantarabenjakul W; Phasomsap C; Chumket S; Yoksan S; Pancharoen C
    Vaccine; 2016 Oct; 34(44):5279-5283. PubMed ID: 27628323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term immunogenicity of an initial booster dose of an inactivated, Vero cell culture-derived Japanese encephalitis vaccine (JE-VC) and the safety and immunogenicity of a second JE-VC booster dose in children previously vaccinated with an inactivated, mouse brain-derived Japanese encephalitis vaccine.
    Yun KW; Lee HJ; Park JY; Cho HK; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    Vaccine; 2018 Mar; 36(11):1398-1404. PubMed ID: 29429815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO(®)) induced neutralizing antibody titers.
    Van Gessel Y; Klade CS; Putnak R; Formica A; Krasaesub S; Spruth M; Cena B; Tungtaeng A; Gettayacamin M; Dewasthaly S
    Vaccine; 2011 Aug; 29(35):5925-31. PubMed ID: 21723353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A field study on Nakayama and Beijing strains of Japanese encephalitis vaccines.
    Nimmannitya S; Hutamai S; Kalayanarooj S; Rojanasuphot S
    Southeast Asian J Trop Med Public Health; 1995 Dec; 26(4):689-93. PubMed ID: 9139377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of antibodies six years after booster vaccination with inactivated vaccine against Japanese encephalitis.
    Paulke-Korinek M; Kollaritsch H; Kundi M; Zwazl I; Seidl-Friedrich C; Jelinek T
    Vaccine; 2015 Jul; 33(30):3600-4. PubMed ID: 26036947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.
    Monath TP; Guirakhoo F; Nichols R; Yoksan S; Schrader R; Murphy C; Blum P; Woodward S; McCarthy K; Mathis D; Johnson C; Bedford P
    J Infect Dis; 2003 Oct; 188(8):1213-30. PubMed ID: 14551893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a freeze-dried, Vero cell culture-derived, inactivated Japanese encephalitis vaccine (KD-287, ENCEVAC®) versus a mouse brain-derived inactivated Japanese encephalitis vaccine in children: a phase III, multicenter, double-blinded, randomized trial.
    Yun KW; Lee HJ; Kang JH; Eun BW; Kim YJ; Kim KH; Kim NH; Hong YJ; Kim DH; Kim HM; Cha SH
    BMC Infect Dis; 2015 Jan; 15():7. PubMed ID: 25567119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The immunogenicity of tetravalent dengue DNA vaccine in mice pre-exposed to Japanese encephalitis or Dengue virus antigens.
    Prompetchara E; Ketloy C; Keelapang P; Sittisombut N; Ruxrungtham K
    Asian Pac J Allergy Immunol; 2015 Sep; 33(3):182-8. PubMed ID: 26342114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An intranasal challenge model for testing Japanese encephalitis vaccines in rhesus monkeys.
    Raengsakulrach B; Nisalak A; Gettayacamin M; Thirawuth V; Young GD; Myint KS; Ferguson LM; Hoke CH; Innis BL; Vaughn DW
    Am J Trop Med Hyg; 1999 Mar; 60(3):329-37. PubMed ID: 10466957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of current Japanese encephalitis vaccine on different strains of Japanese encephalitis virus.
    Okuno Y; Okamoto Y; Yamada A; Baba K; Yabuuchi H
    Vaccine; 1987 Jun; 5(2):128-32. PubMed ID: 3037813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced neutralizing antibody titer against genotype I virus in swine immunized with a live-attenuated genotype III Japanese encephalitis virus vaccine.
    Fan YC; Chen JM; Chen YY; Lin JW; Chiou SS
    Vet Microbiol; 2013 May; 163(3-4):248-56. PubMed ID: 23415032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of inactivated chromatographically purified Vero cell-derived Japanese encephalitis vaccine in Thai children.
    Chanthavanich P; Limkittikul K; Sirivichayakul C; Chokejindachai W; Hattasingh W; Pengsaa K; Surangsrirat S; Srisuwannaporn T; Kaewma B; Yoksan S; Jun G; Zhumu B
    Hum Vaccin Immunother; 2018 Apr; 14(4):900-905. PubMed ID: 29227177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of Japanese encephalitis chimeric virus vaccine: Immune responses in children.
    Chokephaibulkit K; Sirivichayakul C; Thisyakorn U; Pancharoen C; Boaz M; Bouckenooghe A; Feroldi E
    Vaccine; 2016 Nov; 34(46):5664-5669. PubMed ID: 27686833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low population Japanese encephalitis virus (JEV) seroprevalence in Udayapur district, Nepal, three years after a JE vaccination programme: A case for further catch up campaigns?
    Turtle L; Brindle HE; Schluter WW; Faragher B; Rayamajhi A; Bohara R; Gurung S; Shakya G; Yoksan S; Dixit S; Rajbhandari R; Paudel B; Adhikari S; Solomon T; Griffiths MJ
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007269. PubMed ID: 30986252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.